Related Funds
| Fund Name | Location |
| Action Hero Ventures | South Africa, Stellenbosch, Western Cape |
| Affirma Capital | England, London, United Kingdom |
| Changrun Jinkong | China, Guangdong, Shenzhen |
| Commonwealth's Opportunity Fund | - |
| Crescat Capital | Colorado, Denver, United States |
| Donghan International | - |
| Haitong Securities | China, Shanghai |
| HuaJin Securities | China, Shanghai |
| Koerner Capital | Louisiana, New Orleans, United States |
| leAD Sports & Health Tech Partners | Berlin, Berlin, Germany |
| Moonstone Capital | England, London, United Kingdom |
| Omega Pharmaceuticals | England, London, United Kingdom |
| Predictive VC | - |
| Rumford | Bavaria, Germany, Munich |
| Seazen | China, Guangxi, Zhongjiang |
| The Judd Leighton Foundation | - |
| Yixin Touzi | Beijing, Beijing, China |
| Zhangsheng Guquan | China, Shanxi, Xinjiang |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Geneos Therapeutics | $5M | 27 Sep 2023 | Whitemarsh Township, Pennsylvania, United States | ||
ReLive | $43M | 16 Jan 2023 | - | ||
ArriVent Biopharma | $155M | 29 Dec 2022 | Pennsylvania Furnace, Pennsylvania, United States | ||
Ranok Therapeutics | $40M | 19 Aug 2021 | Hangzhou, Zhejiang, China | ||
Immvira | $10M | 24 Sep 2020 | Futian District, Guangdong Province | ||
VeriSilicon Holdings | 03 Sep 2018 | Shanghai, China |
– Ranok Therapeutics (Hangzhou) Co. Ltd. secured a $40m Series B funding round denominated in both U.S. dollars and Chinese yuan.
– The financing was led by Lapam Capital and Shanghai Healthcare Capital, with additional participation from Wu Capital, Zhongguancun Kaiyuan Capital and existing investors, and representatives of the new investors will join Ranok’s expanded board of directors.
– To date, Ranok has raised the equivalent of over $50m in funding.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Geneos Therapeutics | $5M | 27 Sep 2023 | Whitemarsh Township, Pennsylvania, United States | ||
ReLive | $43M | 16 Jan 2023 | - | ||
ArriVent Biopharma | $155M | 29 Dec 2022 | Pennsylvania Furnace, Pennsylvania, United States | ||
Ranok Therapeutics | $40M | 19 Aug 2021 | Hangzhou, Zhejiang, China | ||
Immvira | $10M | 24 Sep 2020 | Futian District, Guangdong Province | ||
VeriSilicon Holdings | 03 Sep 2018 | Shanghai, China |
